DaVita (DVA)
(Delayed Data from NYSE)
$164.82 USD
+0.25 (0.15%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $164.77 -0.05 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
DVA 164.82 +0.25(0.15%)
Will DVA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for DVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DVA
DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts
Catalent Stock Flat Following the Sell Agreement With Ardena
DVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
HealthEquity Gains 28.3% YTD: What's Driving the Stock?
Acadia Healthcare Ventures in South Carolina With Three Buyouts
Centene's Meridian Unit Wins Michigan Contract for HIDE SNP Plan
Other News for DVA
DaVita Inc (DVA) Trading 3.05% Higher on Oct 15
Moderna continues to be the most shorted S&P 500 healthcare stock in September
Universal Health Services, DaVita, HCA Healthcare among top healthcare Quant picks before Q3 earnings
IYH: Healthcare Dashboard For October
DaVita Reaches Analyst Target Price